Zhongzhi Pharmaceutical Holdings Ltd. has issued a profit warning, indicating a significant decline in its financial performance for the first half of 2025. The company anticipates a decrease in net profit of approximately 90% compared to the same period in the previous year. This downturn is attributed to adjustments in industry policies that have led to a short-term drop in sales revenue, subsequently affecting profitability. Despite these challenges, the company remains committed to market investment and is actively seeking new business growth opportunities. Shareholders and potential investors are advised to exercise caution when dealing with the company's shares and to await the publication of the full unaudited consolidated results by the end of August 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。